Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient

BMC Infectious Diseases

Detlef Michel³  Thomas Mertens³  Eva Gentner³  Susanne Schuler-Luettmann¹  Karoline Ehlert²  Axel Schubert³ 

[1] Institut für Medizinische Mikrobiologie, Klinische Virologie, Von-Stauffenberg-Str. 36, 48151 Münster, Germany;Klinik und Poliklinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany;Institut für Virologie, Universitätsklinikum Ulm, Albert-Einstein-Allee 11, 89081 Ulm, Germany

关键词: Bone marrow transplantation;    Foscarnet;    Ganciclovir;    Maribavir;    Cytomegalovirus;    Antiviral resistance;   

Others  :  1146929
DOI  :  10.1186/1471-2334-13-330

 received in 2013-02-06, accepted in 2013-07-16,  发布年份 2013

【 摘 要 】

Background

Human cytomegalovirus infections are still significant causes of morbidity and mortality in transplant recipients. The use of antiviral agents is limited by toxicity and evolving resistance in immunocompromised patients with ongoing viral replication during therapy. Here, we present the first documented case of genotypic resistance against maribavir in a bone marrow transplant (BMT) recipient.

Case presentation

The female 13-year-old patient was suffering from a refractory cytopenia. Ganciclovir, foscarnet, cidofovir, leflunomide and maribavir, an inhibitor of the cytomegalovirus UL97 protein, were administered to treat a therapy-resistant cytomegalovirus infection. Viral mutations conferring resistance against nucleotide and pyrophosphate analogs as well as maribavir (MBV) have evolved sequentially. Particularly, impressive was the fast emergence of multiple mutations T409M, H411Y and H411N conferring maribavir resistance after less than 6 weeks.

Conclusion

We describe the fast emergence of cytomegalovirus variants with different maribavir resistance associated mutations in a bone marrow transplant recipient treated with MBV 400 mg p.o. twice per day. The results suggest that a high virus load permitted a selection of several but distinct therapy-resistant HCMV mutants. Since a phase II study with MBV is intended for the treatment of resistant or refractory HCMV infections in transplant recipients this has to be kept in mind in patients with high viral loads during therapy (NCT01611974).

【 授权许可】

   
2013 Schubert et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Michel D, Mertens T: The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: impact on virus and host. Biochim Biophys Acta 2004, 1697:169-180.
• [2]Schreiber A, Harter G, Schubert A, Bunjes D, Mertens T, Michel D: Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother 2009, 10:191-209.
• [3]Lurain NS, Chou S: Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010, 23:689-712.
• [4]Biron KK, Harvey RJ, Chamberlain SC, et al.: Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002, 46:2365-2372.
• [5]Hakki M, Chou S: The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis 2011, 24:605-611.
• [6]Lalezari JP, Aberg JA, Wang LH, et al.: Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 2002, 46:2969-2976.
• [7]Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB: Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003, 47:1334-1342.
• [8]Winston DJ, Young JA, Pullarkat V, et al.: Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008, 111:5403-5410.
• [9]Marty FM, Ljungman P, Papanicolaou GA, et al.: Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011, 11:284-292.
• [10]Avery RK, Marty FM, Strasfeld L, et al.: Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010, 12:489-496.
• [11]Strasfeld L, Lee I, Tatarowicz W, Villano S, Chou S: Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis 2010, 202:104-108.
• [12]Michel D, Hohn S, Haller T, Jun D, Mertens T: Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein. J Med Virol 2001, 65:70-66.
• [13]Ijichi O, Michel D, Mertens T, Miyata K, Eizuru Y: GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E. Antiviral Res 2002, 53:135-142.
• [14]Chou S, Marousek GI, Van Wechel LC, Li S, Weinberg A: Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 2007, 51:4160-4152.
• [15]Chou S, Wechel LC, Marousek GI: Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007, 196:91-84.
• [16]National Institute of Health: Clinicaltrials.gov NCT01611974: Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients. ViroPharma; 2013.